Zhongzhi Pharmaceutical Holdings Limited (HK:3737)
:3737
Want to see HK:3737 full AI Analyst Report?
3737 Stock Chart & Stats
HK$0.88
HK$0.04(4.04%)
At close: 4:00 PM EST
HK$0.88
HK$0.04(4.04%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$0.98
Previous CloseN/A
Volume157.00K
Average Volume (3M)412.77K
Market Cap
HK$559.02M
Enterprise ValueHK$565.43M
Total Cash (Recent Filing)HK$200.89M
Total Debt (Recent Filing)HK$227.02M
Price to Earnings (P/E)28.1
Beta0.01
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.43%
Share Statistics
EPS (TTM)0.02
Shares Outstanding863,600,000
10 Day Avg. Volume391,300
30 Day Avg. Volume412,766
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.40
Price to Sales (P/S)0.25
P/FCF Ratio6.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModest leverage and a stable equity base reduce solvency risk and provide financing optionality. A conservative balance sheet supports capital allocation through downturns, enabling the company to fund operations, invest selectively, or sustain distributions without forced asset sales.
Positive Free Cash FlowSustained positive free cash flow—even after a drop—signals underlying cash-generative operations. That durable cash generation improves financial flexibility for R&D, capex, or dividend support and lowers reliance on external financing over a multi-month horizon.
Healthy Gross MarginA high gross margin indicates strong product economics and potential pricing power. Even with current cost pressures, robust gross profitability provides a structural cushion to restore operating margins if SG&A or manufacturing efficiencies improve.
Bears Say
Sharp Revenue DeclineA marked drop in revenue reduces scale benefits and weakens long-term growth visibility. Persistent top-line contraction undermines the company’s ability to cover fixed costs, erodes bargaining power with suppliers, and limits the runway for reinvestment and margin recovery.
Falling Free Cash Flow And VolatilityA nearly 50% decline in FCF signals weaker conversion of profits to cash or rising working capital/capex needs. Sustained volatility in cash generation hampers planning, reduces buffer for investments or dividends, and raises the risk of funding shortfalls during stress periods.
Declining Returns And Operating ProfitabilitySharp falls in ROE and operating margin point to deteriorating capital efficiency and operational performance. Persistently low returns constrain the firm’s ability to generate shareholder value and may necessitate strategic changes to restore long-term profitability.
Zhongzhi Pharmaceutical Holdings Limited News
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$0.98 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$559.02M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date is Aug 20, 2026 which is in 69 days.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.011.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Zhongzhi Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays a Annually dividend of HK$0.05 which represents an annual dividend yield of 9.43%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.176%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.77%
12-Months-Change
Fundamentals
Return on Equity
1.57%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---